Skip to main content
Explore URMC

menu

Leukemia: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (ALL)

Research Question:
What are the affects (good and bad) of the drug blinatumomab on your type of cancer (BCR/ABL negative ALL)? (This drug will be added to what has traditionally been used to treat your specific cancer sub-type.)

Basic Study Information

Purpose:
Studies are being done in ALL and other blood cancers with blinatumomab. It is hoped that blinatumomab will target your B-cell ALL and destroy these specific cells, but it has not yet been proven.

Location: Cancer Center
Study Web URL:  http://clinicaltrials.gov/ct2/show/NCT02003222?term=E1910&rank=1
Study Reference #: CLEU-14018

Lead Researcher (Principal Investigator)

Lead Researcher: Kristen O'Dwyer

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 276-4415
Email: Haley_Misch@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Acute lymphoblastic leukemia [ALL]

Return to Search